Abstract 555P
Background
Approximately half of non-small cell lung cancer (NSCLC) patients are diagnosed at a metastatic stage. Molecular testing is vital for identifying druggable mutations in these patients. This prospective study aimed to assess the quality of life (QoL) of these patients and differences in QoL between patients with or without druggable mutations.
Methods
Patients newly diagnosed with stage IV NSCLC after March 2021 from the seven public oncology centres in Hong Kong were eligible. Mutation profiling was performed using next-generation sequencing with FoundationOne CDx. QoL assessments were conducted at baseline and then at 3, 6, 9, and 12 months using validated EORTC QLQ-C30 and EQ-5D-5L questionnaires.
Results
A total of 580 patients were included. Statistically significant changes in various aspects of QoL were observed over time, including global health status (QL), physical functioning (PF), role functioning (RF), emotional functioning (EF), social functioning (SF), as well as symptoms such as fatigue, pain, dyspnoea, and insomnia (all p < 0.05). There was also significant change in all 5 aspects of EQ-5D-5L and utility score over time. Overall, most improvements in functional and symptom scales were observed in the first 3-6 months’ follow-up. Among the 241 patients with at least 3 months’ follow-up, compared to those without druggable mutations, those with druggable mutations demonstrated better QL at 3- and 12-month (mean difference (MD) 6.11, p=0.04; MD 19.56, p=0.01, respectively), PF at 3-, 6-, and 12-month (MD 12.76, p=0.001; MD 14.62, p=0.01; MD 22.55, p=0.02), EF at 12-month (MD 21.76, p = 0.001), and SF at 6- and 12-month (MD 14.51, p=0.02; MD 21.86, p=0.04); improved pain at 6- and 12-month (MD 14.44, p = 0.03; MD 36.57, p = 0.02), dyspnoea at 3-month (MD 18.23, p<0.001) and appetite at 6-month (MD 15.23, p = 0.04). They also had higher utility scores at 3- and 6-month intervals (MD 0.13, p = 0.04; MD 0.23, p = 0.05).
Conclusions
In conclusion, this study demonstrated improvements in QoL and symptom relief in newly diagnosed stage IV NSCLC patients within the first 3-6 months in Hong Kong. Patients with druggable mutations generally experienced better QoL compared to those without.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The University of Hong Kong.
Funding
Roche.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
623P - Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer
Presenter: Sam Martin
Session: Poster Display
Resources:
Abstract
624P - Pan-cancer single-cell isoform atlas: Unraveling isoform dynamics in cancer immunotherapy
Presenter: Lu Pan
Session: Poster Display
Resources:
Abstract
625P - The association of tumor marker concentration and air pollution in cancer survivors and the general population
Presenter: Kyae Hyung Kim
Session: Poster Display
Resources:
Abstract
626P - Percentage of cancer patients undergoing adjusted targeted therapy after ctDNA testing: Insights from a tertiary hospital experience
Presenter: Jisook Yim
Session: Poster Display
Resources:
Abstract
627P - Racial disparities in synchronous and metachronous colorectal and prostate cancer: SEER based study 2000-2020
Presenter: Taha Nagib
Session: Poster Display
Resources:
Abstract